Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins
Corona virus disease 2019 (COVID-19) is a respiratory disease caused by a new coronavirus (SARS-CoV-2) which causes significant morbidity and mortality. The emergence of this novel and highly pathogenic SARS-CoV-2 and its rapid international spread poses a serious global public health emergency. To...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-11-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844020322647 |
id |
doaj-92725140b15b4446ab2a497cf3ddbc22 |
---|---|
record_format |
Article |
spelling |
doaj-92725140b15b4446ab2a497cf3ddbc222020-12-09T06:24:57ZengElsevierHeliyon2405-84402020-11-01611e05421Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteinsHardy Weisshoff0Oxana Krylova1Heike Nikolenko2Hans-Dirk Düngen3Andre Dallmann4Susanne Becker5Peter Göttel6Johannes Müller7Annekathrin Haberland8Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Straße 2, 12489 Berlin, GermanyLeibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP), Robert-Rössle-Str. 10, 13125 Berlin, GermanyLeibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP), Robert-Rössle-Str. 10, 13125 Berlin, GermanyDepartment of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité-Universitätsmedizin, Augustenburger Platz 1, 13353 Berlin, GermanyDepartment of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Straße 2, 12489 Berlin, GermanyBerlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, GermanyBerlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, GermanyBerlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, GermanyBerlin Cures GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany; Corresponding author.Corona virus disease 2019 (COVID-19) is a respiratory disease caused by a new coronavirus (SARS-CoV-2) which causes significant morbidity and mortality. The emergence of this novel and highly pathogenic SARS-CoV-2 and its rapid international spread poses a serious global public health emergency. To date 32,174,627 cases, of which 962,613 (2.99%) have died, have been reported (https://www.who.int/westernpacific/health-topics/coronavirus, accessed 23 Sep 2020). The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.There are still not many SARS-CoV-2-specific and effective treatments or vaccines available. A second round of infection is obviously unavoidable.Aptamers had already been at the centre of interest in the fight against viruses before now. The selection and development of a new aptamer is, however, a time-consuming process. We therefore checked whether a clinically developed aptamer, BC 007, which is currently in phase 2 of clinical testing for a different indication, would also be able to efficiently bind DNA-susceptible peptide structures from SARS-CoV-2-spreading crucial proteins, such as the receptor binding domain (RBD) of the spike protein and the RNA dependent RNA polymerase of SARS-CoV-2 (re-purposing). Indeed, several such sequence-sections have been identified. In particular for two of these sequences, BC 007 showed specific binding in a therapy-relevant concentration range, as shown in Nuclear magnetic resonance (NMR)- and Circular dicroism (CD)-spectroscopy and isothermal titration calorimetry (ITC). The excellent clinical toxicity and tolerability profile of this substance opens up an opportunity for rapid clinical testing of its COVID-19 effectiveness.http://www.sciencedirect.com/science/article/pii/S2405844020322647AntiviralAptamerBC 007COVID-19Re-purposingSARS-CoV-2 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hardy Weisshoff Oxana Krylova Heike Nikolenko Hans-Dirk Düngen Andre Dallmann Susanne Becker Peter Göttel Johannes Müller Annekathrin Haberland |
spellingShingle |
Hardy Weisshoff Oxana Krylova Heike Nikolenko Hans-Dirk Düngen Andre Dallmann Susanne Becker Peter Göttel Johannes Müller Annekathrin Haberland Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins Heliyon Antiviral Aptamer BC 007 COVID-19 Re-purposing SARS-CoV-2 |
author_facet |
Hardy Weisshoff Oxana Krylova Heike Nikolenko Hans-Dirk Düngen Andre Dallmann Susanne Becker Peter Göttel Johannes Müller Annekathrin Haberland |
author_sort |
Hardy Weisshoff |
title |
Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins |
title_short |
Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins |
title_full |
Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins |
title_fullStr |
Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins |
title_full_unstemmed |
Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins |
title_sort |
aptamer bc 007 - efficient binder of spreading-crucial sars-cov-2 proteins |
publisher |
Elsevier |
series |
Heliyon |
issn |
2405-8440 |
publishDate |
2020-11-01 |
description |
Corona virus disease 2019 (COVID-19) is a respiratory disease caused by a new coronavirus (SARS-CoV-2) which causes significant morbidity and mortality. The emergence of this novel and highly pathogenic SARS-CoV-2 and its rapid international spread poses a serious global public health emergency. To date 32,174,627 cases, of which 962,613 (2.99%) have died, have been reported (https://www.who.int/westernpacific/health-topics/coronavirus, accessed 23 Sep 2020). The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020.There are still not many SARS-CoV-2-specific and effective treatments or vaccines available. A second round of infection is obviously unavoidable.Aptamers had already been at the centre of interest in the fight against viruses before now. The selection and development of a new aptamer is, however, a time-consuming process. We therefore checked whether a clinically developed aptamer, BC 007, which is currently in phase 2 of clinical testing for a different indication, would also be able to efficiently bind DNA-susceptible peptide structures from SARS-CoV-2-spreading crucial proteins, such as the receptor binding domain (RBD) of the spike protein and the RNA dependent RNA polymerase of SARS-CoV-2 (re-purposing). Indeed, several such sequence-sections have been identified. In particular for two of these sequences, BC 007 showed specific binding in a therapy-relevant concentration range, as shown in Nuclear magnetic resonance (NMR)- and Circular dicroism (CD)-spectroscopy and isothermal titration calorimetry (ITC). The excellent clinical toxicity and tolerability profile of this substance opens up an opportunity for rapid clinical testing of its COVID-19 effectiveness. |
topic |
Antiviral Aptamer BC 007 COVID-19 Re-purposing SARS-CoV-2 |
url |
http://www.sciencedirect.com/science/article/pii/S2405844020322647 |
work_keys_str_mv |
AT hardyweisshoff aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT oxanakrylova aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT heikenikolenko aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT hansdirkdungen aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT andredallmann aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT susannebecker aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT petergottel aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT johannesmuller aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins AT annekathrinhaberland aptamerbc007efficientbinderofspreadingcrucialsarscov2proteins |
_version_ |
1724388439686643712 |